C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2026)

C4 Therapeutics has reported Net Cash Flow for 8 years, with the latest figure at -$13.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 216.9% year-over-year to -$13.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (up 126.02% YoY), and the FY2025 full-year result was $19.1 million, up 126.87% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$13.3 million, down from $15.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $65.6 million in Q4 2023, with the low at -$36.9 million in Q1 2024.
• Average Net Cash Flow over 5 years is -$863882.4, with a median of -$4.6 million recorded in 2023.
• Year-over-year, Net Cash Flow slumped 287.26% in 2024 and soared 480.58% in 2025.
• Tracing CCCC's Net Cash Flow over 5 years: stood at -$19.8 million in 2022, then surged by 431.4% to $65.6 million in 2023, then plunged by 106.33% to -$4.1 million in 2024, then soared by 480.58% to $15.8 million in 2025, then tumbled by 184.39% to -$13.3 million in 2026.
• The last three Net Cash Flow figures came in at -$13.3 million (Q1 2026), $15.8 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.

Peer Comparison